Compare COGT & PACS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COGT | PACS |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.5B |
| IPO Year | 2018 | 2024 |
| Metric | COGT | PACS |
|---|---|---|
| Price | $36.44 | $37.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | $32.08 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 1.8M | 959.3K |
| Earning Date | 02-27-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 176.35 |
| EPS | N/A | ★ 1.04 |
| Revenue | N/A | ★ $5,138,841,000.00 |
| Revenue This Year | N/A | $32.53 |
| Revenue Next Year | N/A | $7.71 |
| P/E Ratio | ★ N/A | $36.36 |
| Revenue Growth | N/A | ★ 37.58 |
| 52 Week Low | $3.72 | $7.50 |
| 52 Week High | $43.73 | $43.08 |
| Indicator | COGT | PACS |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 59.48 |
| Support Level | $35.50 | $37.60 |
| Resistance Level | $38.19 | $39.81 |
| Average True Range (ATR) | 1.70 | 1.79 |
| MACD | -0.11 | 0.26 |
| Stochastic Oscillator | 38.19 | 88.99 |
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
PACS Group Inc is a post-acute healthcare company mainly focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.